Pharma & drug development · Reference
What is drug development?
Drug development is the end-to-end process of turning a promising compound into an approved medicine. It runs from target identification and preclinical testing through the clinical-trial phases to regulatory review, with attrition at every stage.
From target to candidate
Drug development begins where drug discovery ends: with a candidate compound chosen because it acts on a biological target thought to influence a disease. Before it can be tested in people, the candidate goes through preclinical work — laboratory and animal studies that characterise how it behaves, its pharmacokinetics and pharmacodynamics, and its safety profile through toxicology testing. Only candidates with an acceptable preclinical profile progress to clinical testing, which begins after an Investigational New Drug application clears the regulator.
Clinical phases and progression
Human testing proceeds through the clinical-trial phases — broadly Phase 1 for initial safety, Phase 2 for early effectiveness, and Phase 3 for large confirmatory comparison, all run to Good Clinical Practice. Each phase is a gate: a candidate advances only if the accumulating evidence supports it. Attrition is high and intentional — stopping a candidate that is unsafe or ineffective is a success of the process, not a failure of it. Because every stage adds cost and time, this staged design concentrates resources on the candidates most likely to benefit patients.
Approval and beyond
Once trials are complete, the evidence is assembled into a marketing application — an NDA or BLA in the United States — and submitted through the FDA approval process or the equivalent at the EMA or MHRA. Regulators weigh benefits against risks, examine manufacturing quality under Good Manufacturing Practice, and decide whether to approve.
Approval is a milestone, not the finish line: pharmacovigilance continues to monitor the medicine in real-world use, and post-market findings can change how it is labelled or used. Drug development is therefore best understood as a long, gated, evidence-driven pipeline rather than a single event.
Key facts
At a glance
- Definition: Process from candidate molecule to approved medicine
- Preclinical: Lab and animal studies before human testing
- Clinical: Phase 1/2/3 trials under Good Clinical Practice
- Gated: Each stage must support progression to the next
- Attrition: Most candidates stop before approval
- Post-market: Pharmacovigilance continues after launch
Common questions
FAQ
What are the stages of drug development?+
Drug development moves from target identification and candidate selection, through preclinical testing, into Phase 1, 2 and 3 clinical trials, and then to regulatory review and approval. Post-market monitoring follows. This describes the process at an educational level and is not medical advice.
How is drug development different from drug discovery?+
Drug discovery is the earlier science of finding and optimising candidate compounds, while drug development is the later, highly regulated process of testing a selected candidate in preclinical and clinical studies and seeking approval. Discovery feeds development.
Why do so many drug candidates fail?+
Candidates are stopped when evidence shows they are unsafe, ineffective or no better than existing options. High attrition is an expected feature of the staged process, which is designed to halt unpromising candidates before large, costly trials.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
